Immune Tolerance Network logo — The Immune Tolerance Network (ITN) is a collaborative networ...

Immune Tolerance Network

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of

36 employees

General Information

Company Name Immune Tolerance Network
Employees 36
Social

Get notified when Immune Tolerance Network moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immune Tolerance Network

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The organization's mission is to accelerate the clinical development of immune tolerance therapies in asthma and allergy, autoimmune diseases, type 1 diabetes, and solid organ transplantation. Immune tolerance therapies fundamentally reprogram the immune system, effectively halting disease-causing immune responses while preserving the system's ability to combat pathogen infection. The ITN's approach involves developing, funding, and conducting clinical trials in conjunction with mechanistic, laboratory-based studies. As a venture capital analyst, I find the ITN's mission and objectives aligned with the growing need for innovative therapies targeting various conditions. The potential impact of immune tolerance therapies in addressing prevalent health challenges such as autoimmune diseases and organ transplantation is significant. The organization's collaboration with the National Institutes of Health also signals credibility and potential for impactful research outcomes. The absence of specific details on the ITN's founding date, industries, headquarters, investments, and investors presents limitations in fully evaluating its operational and financial standing. Knowing these details would be crucial for forming a comprehensive assessment of its potential for investment and partnership opportunities. In conclusion, while the Immune Tolerance Network shows promise in advancing critical clinical research areas, further information on its establishment, industry focus, and financial backing is needed to fully assess its potential for investment and collaboration.

Taxonomy: immune tolerance, clinical research, immune therapies, autoimmune diseases, type 1 diabetes, solid organ transplantation, clinical trials, mechanistic studies, laboratory-based research, allergy, NIH-funded, immune system, asthma, pathogen infection, National Institute of Allergy and Infectious Diseases

No funding data available for Immune Tolerance Network yet.

Get notified when Immune Tolerance Network raises funding

Immune Tolerance Network Alternatives & Competitors

Immune Tolerance Network vs
SQZ Biotechnologies
SQZ Biotechnologies United States

Unlocking the full potential of cell therapies for patients around the world

Grant
18 employees
Biotechnology, Health and Wellness
Immune Tolerance Network vs

Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases.

Immune Tolerance Network vs
Beeline Medicines
Beeline Medicines United States

Let’s get to what matters. To life lived fully.

38 employees

FAQ About Immune Tolerance Network

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of
Immune Tolerance Network has approximately 36 employees.
Top alternatives and competitors to Immune Tolerance Network include SQZ Biotechnologies, RegCell, Beeline Medicines, Third Harmonic Bio, COUR Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immune Tolerance Network and SQZ Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immune Tolerance Network and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy